Quarterly ResultMay 6, 2026, 07:32 AM
TG Therapeutics Q1 Revenue $205M; Raises 2026 BRIUMVI Guidance to $885-900M
AI Summary
TG Therapeutics reported strong first quarter 2026 financial results, with total global revenue of $204.9 million and U.S. BRIUMVI net revenue of $194.8 million, representing 63% quarterly growth year-over-year. Net income increased to $19.8 million, or $0.12 diluted EPS. The company significantly raised its full-year 2026 total global revenue target to approximately $925 million and its U.S. BRIUMVI net product revenue target to $885-$900 million. Additionally, TG Therapeutics secured $500 million in non-dilutive capital and expanded its share repurchase program to $300 million.
Key Highlights
- Q1 2026 total global revenue was $204.9 million.
- Q1 2026 BRIUMVI U.S. net revenue was $194.8 million, up 63% YoY.
- Q1 2026 net income was $19.8 million; diluted EPS $0.12.
- Raises full-year 2026 global revenue guidance to $925 million.
- Raises full-year 2026 BRIUMVI U.S. revenue guidance to $885-900 million.
- Secured $500 million in non-dilutive capital from Blue Owl Capital.
- Expanded share repurchase program to $300 million, with $200 million remaining.
- Cash, cash equivalents, and investments were $572.8 million as of March 31, 2026.